This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
GTHX Overzicht aandelen
A commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 6/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
G1 Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$7.15 |
| 52 Week Hoogtepunt | US$7.19 |
| 52 Week Laag | US$1.08 |
| Bèta | 1.68 |
| 11 maand verandering | 0.85% |
| 3 maanden verandering | 182.61% |
| 1 Jaar Verandering | 433.58% |
| 33 jaar verandering | -52.55% |
| 5 jaar verandering | -78.80% |
| Verandering sinds IPO | -52.33% |
Recent nieuws en updates
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Rendement voor aandeelhouders
| GTHX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.3% | -2.6% | -0.7% |
| 1Y | 433.6% | 17.5% | 30.3% |
Rendement versus industrie: GTHX exceeded the US Biotechs industry which returned 20.4% over the past year.
Rendement versus markt: GTHX exceeded the US Market which returned 25.3% over the past year.
Prijsvolatiliteit
| GTHX volatility | |
|---|---|
| GTHX Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: GTHX's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: GTHX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2008 | 100 | Jack Bailey | www.g1therapeutics.com |
G1 Therapeutics, Inc. Samenvatting
| GTHX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$378.17m |
| Inkomsten(TTM) | -US$44.77m |
| Inkomsten(TTM) | US$58.20m |
6.5x
P/S-verhouding-8.4x
Koers/WinstverhoudingIs GTHX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| GTHX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$58.20m |
| Kosten van inkomsten | US$6.14m |
| Brutowinst | US$52.05m |
| Overige uitgaven | US$96.82m |
| Inkomsten | -US$44.77m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.85 |
| Brutomarge | 89.44% |
| Nettowinstmarge | -76.93% |
| Schuld/Eigen Vermogen Verhouding | 180.2% |
Hoe presteerde GTHX op de lange termijn?
Bekijk historische prestaties en vergelijking